期刊文献+

蒿甲醚-蔗糖铁脂质纳米粒的制备及表征 被引量:1

Preparation and Characterization of Artemether-iron Sucrose Lipid Nanoparticles
下载PDF
导出
摘要 目的研制蒿甲醚-蔗糖铁脂质纳米粒且表征其理化性质。方法以大豆卵磷脂和大豆油为载体,采用薄膜分散-高压乳匀法制备蒿甲醚-蔗糖铁脂质纳米粒。用高效液相色谱法测定包封率和载药量,用电子显微镜观察形态,用激光粒度仪测定粒径。结果制得的脂质纳米粒呈类球状,粒径较均匀,平均粒径为(161±17.4)nm,包封率为(85.1±0.83)%,载药量为(5.3±0.2)%。体外释放实验表明,脂质纳米粒具有良好的缓释特征。结论该制备工艺简单可行,制得的纳米粒分散均匀,包封率较高。 Objective To prepare Artemether-Iron Sucrose lipid nanoparticles and examine the characteristics of the nanoparticles. Methods The Artemether-Iron Sucrose lipid nanoparticles were prepared by film-dispersing and high-pressure homegenization technique using soybean phospholipid and soybean oil as matrix. The entrapment efficiency and drug loading capacity were determined by HPLC. The morphology was examined by transmission electron microscope and the mean particle size was measured by laser light scattering technique. Results The products were spherical and well distributed. The mean diameter was (161 ± 17.4) nm with (85. 1± 0. 83)% of entrapment efficiency and (5, 3±0. 2)% of drug loading. The in vitro release test showed that the Art-IS-NLC had good sustained release characteristics. Conclusion The preparation method of Art-IS-NLC is simple and feasible. The products are well distributed with a high entrapment efficiency.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2009年第4期724-726,740,共4页 Journal of Sichuan University(Medical Sciences)
关键词 蒿甲醚 蔗糖铁 脂质纳米粒 Artemether Iron sucrose Nanostructured lipid carriers
  • 相关文献

参考文献9

  • 1王年鹤,袁昌齐,吕晔,岳俊三,郭可跃.药用植物稀有濒危程度评价标准的讨论[J].中国中药杂志,1992,17(2):67-70. 被引量:34
  • 2Meshnick SR.Artemisinin:mechanisms of action,resistance and toxicity.Int J Parasitol,2002;32(13):1655-1660.
  • 3Efferth T,Benakis A,Romero MR,et al.Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron.Free Radic Biol Med,2004;37(7):998-1009.
  • 4Lai H,Sasaki T,Singh NP.Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds.Expert Opin Ther Targets,2005;9(5):995-1007.
  • 5Moore JC,Lai H,Li JR,et al.Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat.Cancer Lett,1995;98(1):83-87.
  • 6陈锋,金日显,陈燕军.纳米结构脂质载体的研究进展[J].中国新药杂志,2008,17(6):456-460. 被引量:25
  • 7杨凯亮,陈大为,王书典,姚崇舜,李校堃,胡海洋,赵秀丽,仇德安,姜义娜.莪术油纳米脂质载体给药系统的制备及其评价[J].中国药学杂志,2006,41(24):1881-1884. 被引量:23
  • 8Chimanuka B,Gabriels M,Detaevernier MR,et al.Preparation of β-artemether liposomes,their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice.J Pharm Biomed Anal,2002;28(1):13-22.
  • 9范敏华.静脉铁的临床应用[J].中国血液净化,2006,5(8):407-409. 被引量:26

二级参考文献46

共引文献103

同被引文献25

  • 1Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin-pipera quine versus artemether-lumefantrine for first-line treat ment of uncomplicated malaria in African children:a cost effectiveness analysis[J]. PLoS One, 2014,9 (4) : e95681.
  • 2Patil S,Joshi M, Pathak S, et al. Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation[J]. J Antimicrob Che- mother,2012,67 (11) :2713-2716.
  • 3Eltayeb SE, Su Z,Shi Y,et al. Preparation and optimiza- tion of transferrin-modified-artemether lipid nanospheres based on the orthogonal design of emulsion formulation and physically electrostatic adsorption[J]. Int J Pharm, 2013,452(1/2) :321-332.
  • 4Mandawgade SD, Sharma S, Pathak S,et al. Development of SMEDDS using natural lipophile: application to beta- Artemether delivery [J]. Int J Pharm, 2008, 362 (1/2) : 179-183.
  • 5Jain K, Gowthamarajan K, Sood S, et al. Olfactory drug delivery of artemether-cureumin combination for manage- ment of cerebral malaria[J]. Malar J, 2012,11 (Suppl 1 ) : 51.
  • 6Patil S, Suryavanshi S,Pathak S, et al. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model[J]. Int J Pharm, 2013,455 ( 1/ 2) :229-234.
  • 7Golenser J, Waknine JH, Krugliak M, et al. Current per- spectives on the mechanism of action of artemisinins[J]. Int J Parasitol,2006,36(14):1427-1441.
  • 8William T,Menon J,Rajahram G, et al. Severe plasmodi- um knowlesi malaria in a tertiary care hospital, Sabah,Malaysia[J]. Emerg Infect Dis,2011,17(7):1248-1255.
  • 9Dela Hoz RF, Porras RA, Rico MA, et al. Artesunate+ amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum ma laria in the Colombian Pacific region: a noninferiority trial[J]. Rev Soc Bras Med Trop,2012,45(6):732-738.
  • 10Senn N, Rarau P, Manong D, et al. Effectiveness of ar- temether/lumefantrine for the treatment of uncomplicat ed Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea[J]. Clin Infect Dis, 2013, 56(10) : 1413-1420.

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部